Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Eugene Braunwald, M.D.

Co-Author

This page shows the publications co-authored by Eugene Braunwald and Christopher Cannon.
Connection Strength

16.627
  1. Ezetimibe plus a Statin after Acute Coronary Syndromes. N Engl J Med. 2015 10 08; 373(15):1476-7.
    View in: PubMed
    Score: 0.652
  2. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006 Aug 01; 48(3):438-45.
    View in: PubMed
    Score: 0.344
  3. Intensive lipid lowering with atorvastatin in coronary disease. N Engl J Med. 2005 Jul 07; 353(1):93-6; author reply 93-6.
    View in: PubMed
    Score: 0.320
  4. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol. 2002 Apr 01; 89(7):860-1.
    View in: PubMed
    Score: 0.256
  5. Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry. Crit Pathw Cardiol. 2002 Mar; 1(1):44-52.
    View in: PubMed
    Score: 0.254
  6. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. J Am Coll Cardiol. 2021 Oct 12; 78(15):1499-1507.
    View in: PubMed
    Score: 0.247
  7. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol. 2001 Mar 01; 87(5):636-9, A10.
    View in: PubMed
    Score: 0.237
  8. Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT. JACC CardioOncol. 2020 Sep; 2(3):385-396.
    View in: PubMed
    Score: 0.230
  9. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000 Jul 11; 102(2):149-56.
    View in: PubMed
    Score: 0.227
  10. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 1998 Dec 22-29; 98(25):2805-14.
    View in: PubMed
    Score: 0.203
  11. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):934-943.
    View in: PubMed
    Score: 0.202
  12. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. Am J Cardiol. 1998 Sep 15; 82(6):731-6.
    View in: PubMed
    Score: 0.200
  13. Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation. 2018 06 12; 137(24):2662-2663.
    View in: PubMed
    Score: 0.196
  14. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Circulation. 1998 Feb 03; 97(4):340-9.
    View in: PubMed
    Score: 0.192
  15. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017 Dec 19; 136(25):2440-2450.
    View in: PubMed
    Score: 0.187
  16. Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction. Am J Cardiol. 1997 Sep 15; 80(6):696-9.
    View in: PubMed
    Score: 0.187
  17. Reply: Ezetimibe, Risk Stratification, and Secondary Prevention. J Am Coll Cardiol. 2017 08 29; 70(9):1200.
    View in: PubMed
    Score: 0.186
  18. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol. 1997 Jul; 30(1):133-40.
    View in: PubMed
    Score: 0.184
  19. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017 05 01; 2(5):547-555.
    View in: PubMed
    Score: 0.182
  20. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. J Am Coll Cardiol. 2017 Feb 28; 69(8):911-921.
    View in: PubMed
    Score: 0.180
  21. Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). Am J Cardiol. 1997 Feb 01; 79(3):253-8.
    View in: PubMed
    Score: 0.179
  22. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997 Jan 21; 95(2):351-6.
    View in: PubMed
    Score: 0.178
  23. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J. 2016 Dec; 182:89-96.
    View in: PubMed
    Score: 0.174
  24. Reply: Personalize and Optimize Lipid-Lowering Therapies. J Am Coll Cardiol. 2016 07 19; 68(3):326.
    View in: PubMed
    Score: 0.172
  25. Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful? J Am Coll Cardiol. 2016 06 28; 67(25):3025-6.
    View in: PubMed
    Score: 0.171
  26. Non-Q wave and ST segment depression myocardial infarction: is there a role for thrombolytic therapy? J Am Coll Cardiol. 1996 May; 27(6):1333-4.
    View in: PubMed
    Score: 0.170
  27. Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Circulation. 2016 Mar 29; 133(13):e463.
    View in: PubMed
    Score: 0.169
  28. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol. 2016 Feb 02; 67(4):353-361.
    View in: PubMed
    Score: 0.167
  29. Time to Reperfusion: The Critical Modulator in Thrombolysis and Primary Angioplasty. J Thromb Thrombolysis. 1996; 3(2):117-125.
    View in: PubMed
    Score: 0.166
  30. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015 Sep 29; 132(13):1224-33.
    View in: PubMed
    Score: 0.162
  31. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18; 372(25):2387-97.
    View in: PubMed
    Score: 0.159
  32. Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty. J Am Coll Cardiol. 1995 Jun; 25(7 Suppl):30S-37S.
    View in: PubMed
    Score: 0.159
  33. Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: an analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III trials. Am J Cardiol. 1995 May 15; 75(15):977-81.
    View in: PubMed
    Score: 0.159
  34. GUSTO, TIMI and the case for rapid reperfusion. Acta Cardiol. 1994; 49(1):1-8.
    View in: PubMed
    Score: 0.144
  35. Time as an Adjunctive Agent to Thrombolytic Therapy. J Thromb Thrombolysis. 1994; 1(1):27-34.
    View in: PubMed
    Score: 0.144
  36. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993 Apr 01; 71(10):778-82.
    View in: PubMed
    Score: 0.137
  37. Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. Chronobiol Int. 2012 Dec; 29(10):1390-6.
    View in: PubMed
    Score: 0.133
  38. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):613-619.e1.
    View in: PubMed
    Score: 0.123
  39. Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. Eur Heart J. 2011 Jun; 32(11):1390-7.
    View in: PubMed
    Score: 0.118
  40. Prior aspirin use and outcomes in acute coronary syndromes. J Am Coll Cardiol. 2010 Oct 19; 56(17):1376-85.
    View in: PubMed
    Score: 0.116
  41. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J. 2010 Aug; 31(16):1993-2005.
    View in: PubMed
    Score: 0.113
  42. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010 May; 159(5):705-9.
    View in: PubMed
    Score: 0.111
  43. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009 Dec 15; 54(25):2358-62.
    View in: PubMed
    Score: 0.109
  44. Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. Am Heart J. 2009 Apr; 157(4):673-9.e1.
    View in: PubMed
    Score: 0.103
  45. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2009 Mar; 29(3):424-30.
    View in: PubMed
    Score: 0.102
  46. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. J Am Coll Cardiol. 2008 Sep 09; 52(11):914-20.
    View in: PubMed
    Score: 0.100
  47. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008 Nov; 156(5):826-32.
    View in: PubMed
    Score: 0.100
  48. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol. 2008 Sep 01; 102(5):552-8.
    View in: PubMed
    Score: 0.098
  49. Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy. Am J Cardiol. 2008 May 01; 101(9):1232-8.
    View in: PubMed
    Score: 0.096
  50. Antiplatelet therapy and platelet function testing. Introduction. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I1.
    View in: PubMed
    Score: 0.096
  51. Assessing the current role of platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I10-6.
    View in: PubMed
    Score: 0.096
  52. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I17-20.
    View in: PubMed
    Score: 0.096
  53. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I2-9.
    View in: PubMed
    Score: 0.096
  54. Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I21-7.
    View in: PubMed
    Score: 0.096
  55. Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I28-35.
    View in: PubMed
    Score: 0.096
  56. Antiplatelet therapy and platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I36.
    View in: PubMed
    Score: 0.096
  57. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2008 Jan 29; 51(4):449-55.
    View in: PubMed
    Score: 0.096
  58. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol. 2007 Oct 01; 100(7):1047-51.
    View in: PubMed
    Score: 0.092
  59. Recent trials of lipid lowering. Int J Clin Pract. 2007 Jul; 61(7):1145-59.
    View in: PubMed
    Score: 0.092
  60. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation. 2007 Jun 19; 115(24):3071-8.
    View in: PubMed
    Score: 0.091
  61. Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18. Eur Heart J. 2007 Apr; 28(7):806-13.
    View in: PubMed
    Score: 0.090
  62. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. J Thromb Thrombolysis. 2006 Oct; 22(2):95-102.
    View in: PubMed
    Score: 0.087
  63. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J. 2006 Oct; 27(19):2323-9.
    View in: PubMed
    Score: 0.087
  64. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. J Thromb Thrombolysis. 2006 Aug; 22(1):71-6.
    View in: PubMed
    Score: 0.086
  65. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol. 2006 Jul 04; 48(1):37-42.
    View in: PubMed
    Score: 0.085
  66. Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. Am J Cardiol. 2006 Jun 01; 97(11):1573-7.
    View in: PubMed
    Score: 0.084
  67. Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials). J Thromb Thrombolysis. 2006 Apr; 21(2):119-29.
    View in: PubMed
    Score: 0.084
  68. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation. 2006 Apr 11; 113(14):1745-52.
    View in: PubMed
    Score: 0.084
  69. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation. 2006 Mar 21; 113(11):1406-14.
    View in: PubMed
    Score: 0.084
  70. Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. Am Heart J. 2006 Feb; 151(2):360-6.
    View in: PubMed
    Score: 0.083
  71. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005 May 17; 45(10):1644-8.
    View in: PubMed
    Score: 0.079
  72. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005 Apr 21; 352(16):1646-54.
    View in: PubMed
    Score: 0.079
  73. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. Am Heart J. 2005 Mar; 149(3):444-50.
    View in: PubMed
    Score: 0.078
  74. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 18; 44(4):783-9.
    View in: PubMed
    Score: 0.075
  75. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med. 2004 Aug 03; 141(3):186-95.
    View in: PubMed
    Score: 0.075
  76. The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. Eur Heart J. 2004 Jul; 25(13):1139-45.
    View in: PubMed
    Score: 0.075
  77. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 08; 350(15):1495-504.
    View in: PubMed
    Score: 0.073
  78. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004 Feb 10; 109(5):580-6.
    View in: PubMed
    Score: 0.073
  79. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation. 2004 Feb 24; 109(7):874-80.
    View in: PubMed
    Score: 0.073
  80. Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) acute coronary syndromes Critical Pathway Toolkit. Crit Pathw Cardiol. 2003 Sep; 2(3):153-77.
    View in: PubMed
    Score: 0.070
  81. Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. Clin Chem. 2003 Aug; 49(8):1396-8.
    View in: PubMed
    Score: 0.070
  82. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 2003 Apr 16; 41(8):1264-72.
    View in: PubMed
    Score: 0.069
  83. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003 Feb 11; 107(5):690-5.
    View in: PubMed
    Score: 0.068
  84. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA. 2002 Dec 25; 288(24):3124-9.
    View in: PubMed
    Score: 0.067
  85. Predictors of mortality, coronary angiography, and revascularization in unstable angina pectoris and acute non-ST elevation myocardial infarction (the TIMI III Registry). Am J Cardiol. 2002 Nov 15; 90(10):1154-6.
    View in: PubMed
    Score: 0.067
  86. Assessing the effect of publication of clinical guidelines on the management of unstable angina and non-ST elevation myocardial infarction in the TIMI III (1990-1993) and the GUARANTEE (1995-1996) Registries. Crit Pathw Cardiol. 2002 Sep; 1(3):150-8.
    View in: PubMed
    Score: 0.066
  87. Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. Am J Cardiol. 2002 Aug 01; 90(3):303-5.
    View in: PubMed
    Score: 0.065
  88. The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. J Am Coll Cardiol. 2002 Jul 17; 40(2):238-44.
    View in: PubMed
    Score: 0.065
  89. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002 Apr 16; 105(15):1760-3.
    View in: PubMed
    Score: 0.064
  90. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 2002 Feb 15; 89(4):463-5.
    View in: PubMed
    Score: 0.063
  91. Seasonal variation of myocardial infarct size. Am J Cardiol. 2001 Nov 01; 88(9):1021-4.
    View in: PubMed
    Score: 0.062
  92. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001 Oct 04; 345(14):1014-21.
    View in: PubMed
    Score: 0.062
  93. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001 Sep 19; 286(11):1356-9.
    View in: PubMed
    Score: 0.062
  94. The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol. 2001 Aug 15; 88(4):347-52.
    View in: PubMed
    Score: 0.061
  95. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001 Jun 21; 344(25):1879-87.
    View in: PubMed
    Score: 0.061
  96. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 Feb 16; 143(7):685-695.
    View in: PubMed
    Score: 0.059
  97. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol. 2000 Nov 15; 36(6):1812-7.
    View in: PubMed
    Score: 0.058
  98. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021 Feb 02; 143(5):470-478.
    View in: PubMed
    Score: 0.058
  99. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020 11 21; 396(10263):1637-1643.
    View in: PubMed
    Score: 0.058
  100. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol. 2000 May; 40(5):508-15.
    View in: PubMed
    Score: 0.056
  101. Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. J Am Coll Cardiol. 2000 Feb; 35(2):358-62.
    View in: PubMed
    Score: 0.055
  102. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000 Jan 18; 101(2):125-30.
    View in: PubMed
    Score: 0.055
  103. Redefining medical treatment in the management of unstable angina. Am J Med. 2000 Jan; 108(1):41-53.
    View in: PubMed
    Score: 0.055
  104. Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2019 12 17; 74(24):3013-3022.
    View in: PubMed
    Score: 0.054
  105. Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999 Nov 01; 34(5):1403-12.
    View in: PubMed
    Score: 0.054
  106. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators. Am J Cardiol. 1999 Nov 01; 84(9):976-80.
    View in: PubMed
    Score: 0.054
  107. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. J Am Coll Cardiol. 1999 Oct; 34(4):974-82.
    View in: PubMed
    Score: 0.054
  108. Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B. J Am Coll Cardiol. 1999 Sep; 34(3):739-47.
    View in: PubMed
    Score: 0.053
  109. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019 09 01; 4(9):846-854.
    View in: PubMed
    Score: 0.053
  110. Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. J Am Coll Cardiol. 2019 08 27; 74(8):1057-1068.
    View in: PubMed
    Score: 0.053
  111. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J. 1999 May; 137(5):786-91.
    View in: PubMed
    Score: 0.052
  112. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation. 1999 Apr 20; 99(15):1945-50.
    View in: PubMed
    Score: 0.052
  113. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999 Mar; 33(3):634-9.
    View in: PubMed
    Score: 0.052
  114. Medication Discontinuation in the IMPROVE-IT Trial. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e005041.
    View in: PubMed
    Score: 0.051
  115. Modes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 11 07; 39(42):3810-3820.
    View in: PubMed
    Score: 0.050
  116. Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome. J Am Heart Assoc. 2018 10 16; 7(20):e009077.
    View in: PubMed
    Score: 0.050
  117. Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. Am J Cardiol. 2018 11 01; 122(9):1451-1458.
    View in: PubMed
    Score: 0.050
  118. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998 Jun; 31(7):1460-5.
    View in: PubMed
    Score: 0.049
  119. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018 06 01; 3(6):473-480.
    View in: PubMed
    Score: 0.049
  120. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. Circulation. 1998 Mar 24; 97(11):1042-5.
    View in: PubMed
    Score: 0.048
  121. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. Am J Cardiol. 1998 Mar 15; 81(6):678-81.
    View in: PubMed
    Score: 0.048
  122. Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome. Eur J Prev Cardiol. 2018 05; 25(8):830-838.
    View in: PubMed
    Score: 0.048
  123. Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy. J Am Coll Cardiol. 1998 Feb; 31(2):326-30.
    View in: PubMed
    Score: 0.048
  124. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 04 10; 137(15):1571-1582.
    View in: PubMed
    Score: 0.047
  125. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc. 2017 Nov 18; 6(11).
    View in: PubMed
    Score: 0.047
  126. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial. J Am Heart Assoc. 2017 Oct 24; 6(10).
    View in: PubMed
    Score: 0.047
  127. Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A. Am Heart J. 1997 Oct; 134(4):622-30.
    View in: PubMed
    Score: 0.047
  128. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017 09 28; 377(13):1217-1227.
    View in: PubMed
    Score: 0.046
  129. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1997 Jul; 30(1):141-8.
    View in: PubMed
    Score: 0.046
  130. Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial. Am J Cardiol. 1997 Jul 01; 80(1):21-6.
    View in: PubMed
    Score: 0.046
  131. Management of unstable angina pectoris and non-Q-wave acute myocardial infarction in the United States and Canada (the TIMI III Registry). Am J Cardiol. 1997 Jun 01; 79(11):1441-6.
    View in: PubMed
    Score: 0.046
  132. Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circ Cardiovasc Qual Outcomes. 2017 05; 10(5).
    View in: PubMed
    Score: 0.045
  133. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. Am Heart J. 2017 05; 187:182-190.
    View in: PubMed
    Score: 0.045
  134. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). Am J Cardiol. 1997 Feb 15; 79(4):391-6.
    View in: PubMed
    Score: 0.045
  135. Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. J Am Heart Assoc. 2017 01 11; 6(1).
    View in: PubMed
    Score: 0.044
  136. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996 Oct 31; 335(18):1342-9.
    View in: PubMed
    Score: 0.044
  137. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur Heart J. 2016 Dec 21; 37(48):3576-3584.
    View in: PubMed
    Score: 0.043
  138. Distortion of the terminal portion of the QRS on the admission electrocardiogram in acute myocardial infarction and correlation with infarct size and long-term prognosis (Thrombolysis in Myocardial Infarction 4 Trial). Am J Cardiol. 1996 Aug 15; 78(4):396-403.
    View in: PubMed
    Score: 0.043
  139. Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. J Am Coll Cardiol. 2016 07 19; 68(3):322-323.
    View in: PubMed
    Score: 0.043
  140. Preinfarction angina. N Engl J Med. 1996 Jul 04; 335(1):59-60; author reply 60-1.
    View in: PubMed
    Score: 0.043
  141. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996 Mar 01; 93(5):879-88.
    View in: PubMed
    Score: 0.042
  142. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Am Heart J. 1996 Mar; 131(3):421-33.
    View in: PubMed
    Score: 0.042
  143. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol. 1995 Dec; 26(7):1643-50.
    View in: PubMed
    Score: 0.041
  144. Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. Thrombolysis in Myocardial Infarction (TIMI) II Investigators. J Am Coll Cardiol. 1995 Nov 15; 26(6):1452-6.
    View in: PubMed
    Score: 0.041
  145. The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decade. J Interv Cardiol. 1995 Apr; 8(2):117-35.
    View in: PubMed
    Score: 0.039
  146. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015 Jun 06; 385(9984):2264-2271.
    View in: PubMed
    Score: 0.039
  147. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014 Sep 10; 312(10):1006-15.
    View in: PubMed
    Score: 0.038
  148. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014 Aug; 168(2):205-12.e1.
    View in: PubMed
    Score: 0.037
  149. Use of composite endpoints in thrombolysis trials of acute myocardial infarction. Am J Cardiol. 1993 Dec 16; 72(19):3G-12G.
    View in: PubMed
    Score: 0.036
  150. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). J Am Coll Cardiol. 2014 Jan 28; 63(3):225-32.
    View in: PubMed
    Score: 0.036
  151. Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. J Cardiovasc Pharmacol Ther. 2013 Nov; 18(6):555-9.
    View in: PubMed
    Score: 0.035
  152. An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point. Circulation. 1992 Aug; 86(2):683-7.
    View in: PubMed
    Score: 0.033
  153. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol. 2012 Jul 10; 60(2):106-11.
    View in: PubMed
    Score: 0.033
  154. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem. 2012 Jan; 58(1):267-73.
    View in: PubMed
    Score: 0.031
  155. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22; 305(24):2556-64.
    View in: PubMed
    Score: 0.030
  156. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011 Jan; 31(1):203-10.
    View in: PubMed
    Score: 0.029
  157. Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. Am Heart J. 2010 Jun; 159(6):964-971.e1.
    View in: PubMed
    Score: 0.028
  158. Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62.
    View in: PubMed
    Score: 0.027
  159. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol. 2009 Jun; 4(6):1032-43.
    View in: PubMed
    Score: 0.026
  160. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem. 2009 Feb; 55(2):265-73.
    View in: PubMed
    Score: 0.025
  161. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008 Jul 02; 300(1):71-80.
    View in: PubMed
    Score: 0.025
  162. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008 Feb 19; 51(7):724-30.
    View in: PubMed
    Score: 0.024
  163. The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. Int J Cardiol. 2008 Dec 17; 131(1):105-12.
    View in: PubMed
    Score: 0.024
  164. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. Am Heart J. 2008 Jan; 155(1):133-9.
    View in: PubMed
    Score: 0.024
  165. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008 Jan; 155(1):49-55.
    View in: PubMed
    Score: 0.024
  166. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombolysis. 2008 Oct; 26(2):79-84.
    View in: PubMed
    Score: 0.023
  167. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007 Oct; 53(10):1800-7.
    View in: PubMed
    Score: 0.023
  168. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J. 2006 Oct; 27(19):2310-6.
    View in: PubMed
    Score: 0.022
  169. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006 Jun 06; 47(11):2326-31.
    View in: PubMed
    Score: 0.021
  170. Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. J Clin Hypertens (Greenwich). 2006 May; 8(5):315-22.
    View in: PubMed
    Score: 0.021
  171. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am J Cardiol. 2006 Jul 01; 98(1):1-5.
    View in: PubMed
    Score: 0.021
  172. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation. 2005 Dec 20; 112(25):3846-54.
    View in: PubMed
    Score: 0.021
  173. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18; 46(8):1405-10.
    View in: PubMed
    Score: 0.020
  174. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005 Oct 18; 46(8):1411-6.
    View in: PubMed
    Score: 0.020
  175. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18; 46(8):1417-24.
    View in: PubMed
    Score: 0.020
  176. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005 Sep 14; 294(10):1224-32.
    View in: PubMed
    Score: 0.020
  177. C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial). Am J Cardiol. 2005 Sep 01; 96(5):635-8.
    View in: PubMed
    Score: 0.020
  178. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jul 05; 46(1):178-80.
    View in: PubMed
    Score: 0.020
  179. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005 Jun 15; 293(23):2908-17.
    View in: PubMed
    Score: 0.020
  180. Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. J Am Coll Cardiol. 2005 Jun 07; 45(11):1781-6.
    View in: PubMed
    Score: 0.020
  181. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 Mar 24; 352(12):1179-89.
    View in: PubMed
    Score: 0.020
  182. Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. Am J Cardiol. 2005 Feb 01; 95(3):337-42.
    View in: PubMed
    Score: 0.019
  183. Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. J Am Coll Cardiol. 2005 Feb 01; 45(3):357-62.
    View in: PubMed
    Score: 0.019
  184. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jan 18; 45(2):321-3.
    View in: PubMed
    Score: 0.019
  185. Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. Am J Cardiol. 2005 Jan 15; 95(2):224-7.
    View in: PubMed
    Score: 0.019
  186. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 Jan 06; 352(1):20-8.
    View in: PubMed
    Score: 0.019
  187. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol. 2005 Jan 04; 45(1):19-24.
    View in: PubMed
    Score: 0.019
  188. Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Dec 01; 94(11):1406-10.
    View in: PubMed
    Score: 0.019
  189. Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Nov 01; 94(9):1113-7.
    View in: PubMed
    Score: 0.019
  190. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004 Nov; 25(22):1998-2005.
    View in: PubMed
    Score: 0.019
  191. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). Am J Cardiol. 2004 Sep 15; 94(6):774-6.
    View in: PubMed
    Score: 0.019
  192. Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Sep 01; 44(5):980-7.
    View in: PubMed
    Score: 0.019
  193. A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 18; 44(4):799-803.
    View in: PubMed
    Score: 0.019
  194. Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy). Am J Cardiol. 2004 Aug 15; 94(4):492-4.
    View in: PubMed
    Score: 0.019
  195. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 04; 44(3):564-8.
    View in: PubMed
    Score: 0.019
  196. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. J Am Coll Cardiol. 2004 Apr 07; 43(7):1170-6.
    View in: PubMed
    Score: 0.018
  197. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003 Nov 05; 42(9):1535-43.
    View in: PubMed
    Score: 0.018
  198. Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction. Am J Cardiol. 2003 Oct 15; 92(8):913-8.
    View in: PubMed
    Score: 0.018
  199. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003 Sep 02; 108(9):1049-52.
    View in: PubMed
    Score: 0.018
  200. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003 Jul 02; 42(1):7-16.
    View in: PubMed
    Score: 0.017
  201. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J. 2003 Apr; 145(4):622-7.
    View in: PubMed
    Score: 0.017
  202. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. Am Heart J. 2003 Jan; 145(1):109-17.
    View in: PubMed
    Score: 0.017
  203. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). Am J Cardiol. 2002 Dec 01; 90(11):1246-9.
    View in: PubMed
    Score: 0.017
  204. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy. J Am Coll Cardiol. 2002 Nov 20; 40(10):1761-8.
    View in: PubMed
    Score: 0.017
  205. Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification. Am J Cardiol. 2002 Oct 15; 90(8):821-6.
    View in: PubMed
    Score: 0.017
  206. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. Am Heart J. 2002 Oct; 144(4):649-56.
    View in: PubMed
    Score: 0.017
  207. Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2002 Sep 18; 40(6):1044-50.
    View in: PubMed
    Score: 0.016
  208. The smoker's paradox: insights from the angiographic substudies of the TIMI trials. J Thromb Thrombolysis. 2002 Jun; 13(3):133-9.
    View in: PubMed
    Score: 0.016
  209. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002 Apr 23; 105(16):1909-13.
    View in: PubMed
    Score: 0.016
  210. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood. 2001 Dec 01; 98(12):3256-60.
    View in: PubMed
    Score: 0.016
  211. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001 Nov 21; 286(19):2405-12.
    View in: PubMed
    Score: 0.016
  212. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol. 2001 Oct 15; 88(8):831-6.
    View in: PubMed
    Score: 0.015
  213. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. Am J Cardiol. 2001 Aug 15; 88(4):353-8.
    View in: PubMed
    Score: 0.015
  214. Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy. Am Heart J. 2001 Jul; 142(1):29-36.
    View in: PubMed
    Score: 0.015
  215. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001 May 29; 103(21):2550-4.
    View in: PubMed
    Score: 0.015
  216. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J. 2001 May; 141(5):742-50.
    View in: PubMed
    Score: 0.015
  217. Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group. Am J Cardiol. 2001 Feb 15; 87(4):450-3, A6.
    View in: PubMed
    Score: 0.015
  218. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator. Am Heart J. 2001 Jan; 141(1):33-40.
    View in: PubMed
    Score: 0.015
  219. Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Thrombolysis In Myocardial Infarction. Am J Cardiol. 2000 Dec 15; 86(12):1378-9, A5.
    View in: PubMed
    Score: 0.015
  220. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation. 2000 Nov 07; 102(19):2329-34.
    View in: PubMed
    Score: 0.014
  221. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation. 2000 Jun 13; 101(23):2690-5.
    View in: PubMed
    Score: 0.014
  222. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost. 1998 Jan; 79(1):134-9.
    View in: PubMed
    Score: 0.012
  223. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction. Am J Cardiol. 1996 Sep 01; 78(5):503-10.
    View in: PubMed
    Score: 0.011
  224. How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial) Am J Cardiol. 1995 Feb 01; 75(4):232-6.
    View in: PubMed
    Score: 0.010
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.